GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Optipharm Co Ltd (XKRX:153710) » Definitions » EV-to-FCF

Optipharm Co (XKRX:153710) EV-to-FCF : -27.59 (As of May. 15, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Optipharm Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Optipharm Co's Enterprise Value is ₩95,471 Mil. Optipharm Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-3,460 Mil. Therefore, Optipharm Co's EV-to-FCF for today is -27.59.

The historical rank and industry rank for Optipharm Co's EV-to-FCF or its related term are showing as below:

XKRX:153710' s EV-to-FCF Range Over the Past 10 Years
Min: -8580.65   Med: -33.15   Max: 311.95
Current: -27.13

During the past 11 years, the highest EV-to-FCF of Optipharm Co was 311.95. The lowest was -8580.65. And the median was -33.15.

XKRX:153710's EV-to-FCF is ranked worse than
100% of 99 companies
in the Medical Diagnostics & Research industry
Industry Median: 26.75 vs XKRX:153710: -27.13

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-15), Optipharm Co's stock price is ₩6890.00. Optipharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-166.000. Therefore, Optipharm Co's PE Ratio for today is At Loss.


Optipharm Co EV-to-FCF Historical Data

The historical data trend for Optipharm Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Optipharm Co EV-to-FCF Chart

Optipharm Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -350.71 -78.69 -44.43 -13.42 -28.19

Optipharm Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.42 -16.43 -17.19 -23.49 -28.19

Competitive Comparison of Optipharm Co's EV-to-FCF

For the Diagnostics & Research subindustry, Optipharm Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Optipharm Co's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Optipharm Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Optipharm Co's EV-to-FCF falls into.



Optipharm Co EV-to-FCF Calculation

Optipharm Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=95471.371/-3459.894
=-27.59

Optipharm Co's current Enterprise Value is ₩95,471 Mil.
Optipharm Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-3,460 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Optipharm Co  (XKRX:153710) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Optipharm Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6890.00/-166.000
=At Loss

Optipharm Co's share price for today is ₩6890.00.
Optipharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-166.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Optipharm Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Optipharm Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Optipharm Co (XKRX:153710) Business Description

Traded in Other Exchanges
N/A
Address
6, 63 Osong, Hwaseong-eup, Heungduk-gu, Chungcheongbuk-do, Cheongju, KOR
Optipharm Co Ltd is engaged in developing cell therapy products through animal stem cells, developing high value-added protein drugs using bio-reactors, selecting antibiotic/antiviral components and developing products. Its diagnosis division includes human diagnosis and animal diagnosis that focuses on the development of molecular diagnostics for a variety of diseases.

Optipharm Co (XKRX:153710) Headlines

No Headlines